Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1-11 years at a pediatric tertiary referral hospital in Toronto, Canada.

Publication date: Dec 01, 2024

SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1-11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40. 5%, compared to 19. 3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.

Concepts	Keywords
11years	Antibodies, Viral
Canada	Antibodies, Viral
Hospital	Canada
November	Child
Pandemic	Child, Preschool
	COVID-19
	COVID-19 Vaccines
	COVID-19 Vaccines
	COVID‐19
	Female
	Humans
	Immunocompromised Host
	immunocompromised host
	Infant
	Male
	pediatrics
	public health
	SARS-CoV-2
	SARS‐CoV‐2
	Seroepidemiologic Studies
	seroepidemiological studies
	Tertiary Care Centers

Semantics

Type	Source	Name
disease	MESH	SARS-CoV-2 infection
pathway	REACTOME	SARS-CoV-2 Infection
disease	MESH	infection
disease	MESH	Immunocompromised patients

Original Article

(Visited 3 times, 1 visits today)